Compare Abeona Therapeutics Inc (ABEO) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Global X Defense Tech ETF — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Global X Defense Tech ETF trades at $62.37. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | SHLD | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $78.02 |
52-Week Low | $4.17 | $58.20 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SHLD (Global X Defense Tech ETF) trades at $64.84, up 1.38% with a bullish technical signal supported by moving averages and ADX indicators. The defense sector benefits from global military spending growth, with recent UK defense overhaul and Pentagon AI investments driving positive sentiment. The ETF provides diversified exposure to defense technology companies amid accelerating global rearmament trends.
The outlook remains positive given structural defense spending increases, though competition from other defense ETFs and valuation concerns present risks. Technical indicators suggest potential resistance near $65-66 levels, while sector momentum supports continued investor interest in defense technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
